Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors

#898

Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.

Aim(s): To analyze the impact of two therapies targeting the mTOR pathway (everolimus (EVE) and BEZ235) on tumor apoptosis and activation of key molecules of the mTOR pathway in a model of precision-cut slices culture of PNET.

Materials and methods: Prospective study including 10 PNETs. Fresh tumors were cut using a tissue slicer and cultured with EVE and BEZ235 1 microM for one to two days (D1 and D2), formalin-fixed and cut for immunohistochemistry with cleaved caspase-3, p-Akt, p-mTOR and p-S6 antibodies.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bucau M, Cros J, Rebours V, Albuquerque M, Paradis V,

Keywords: pancreas, targeted therapies, tissue culture, neuroendocrine tumors,